Belumosudil for chronic graft-versus-host disease
Copyright 2022 Clarivate..
Chronic graft-versus-host disease (cGvHD) is a multisystem disease that is diagnosed in up to 70% of patients following allogeneic hematopoietic cell transplantation. In cGvHD, the donor immune cells attack the patient's cells, resulting in inflammation and fibrosis in multiple tissues. cGvHD can affect almost any organ and is the major cause of morbidity and mortality in transplant survivors. Rho-associated coiled-coil-containing protein kinase (ROCK) is a signaling pathway that modulates inflammatory response and fibrotic processes and is dysregulated in autoimmune disorders. Many inhibitors targeting the ROCK pathway have been studied, but most lack isoform selectivity resulting in dose-limiting effects. Belumosudil mesylate is a selective oral ROCK2 inhibitor that has demonstrated safety and efficacy for cGvHD. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years and older with cGvHD after failure of at least two prior lines of systemic therapy, becoming the first and only approved therapy targeting ROCK2. This review examines the preclinical and clinical studies leading to the first approval of the novel drug belumosudil for cGvHD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 58(2022), 5 vom: 13. Mai, Seite 203-212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taylor, Breanna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.05.2022 Date Revised 11.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2022.58.5.3400705 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34064138X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34064138X | ||
| 003 | DE-627 | ||
| 005 | 20231226005840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2022.58.5.3400705 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM34064138X | ||
| 035 | |a (NLM)35535812 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taylor, Breanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Belumosudil for chronic graft-versus-host disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2022 | ||
| 500 | |a Date Revised 11.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2022 Clarivate. | ||
| 520 | |a Chronic graft-versus-host disease (cGvHD) is a multisystem disease that is diagnosed in up to 70% of patients following allogeneic hematopoietic cell transplantation. In cGvHD, the donor immune cells attack the patient's cells, resulting in inflammation and fibrosis in multiple tissues. cGvHD can affect almost any organ and is the major cause of morbidity and mortality in transplant survivors. Rho-associated coiled-coil-containing protein kinase (ROCK) is a signaling pathway that modulates inflammatory response and fibrotic processes and is dysregulated in autoimmune disorders. Many inhibitors targeting the ROCK pathway have been studied, but most lack isoform selectivity resulting in dose-limiting effects. Belumosudil mesylate is a selective oral ROCK2 inhibitor that has demonstrated safety and efficacy for cGvHD. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years and older with cGvHD after failure of at least two prior lines of systemic therapy, becoming the first and only approved therapy targeting ROCK2. This review examines the preclinical and clinical studies leading to the first approval of the novel drug belumosudil for cGvHD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allogeneic hematopoietic cell transplant | |
| 650 | 4 | |a Belumosudil mesylate | |
| 650 | 4 | |a Chronic graft-versus host disease | |
| 650 | 4 | |a Immunomodulators | |
| 650 | 4 | |a ROCK2 inhibitors | |
| 650 | 7 | |a Acetamides |2 NLM | |
| 650 | 7 | |a belumosudil |2 NLM | |
| 650 | 7 | |a rho-Associated Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Cohen, Jaimie |e verfasserin |4 aut | |
| 700 | 1 | |a Tejeda, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Trent Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 58(2022), 5 vom: 13. Mai, Seite 203-212 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2022 |g number:5 |g day:13 |g month:05 |g pages:203-212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2022.58.5.3400705 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2022 |e 5 |b 13 |c 05 |h 203-212 | ||